DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 598-610

  Mancikova, Veronika ^a   Buj, Raquel ^b   Castelblanco, Esmeralda ^c,d   Inglada Pérez, Lucía ^a   Diez, Anna ^b   De Cubas, Aguirre A ^a   Curras Freixes, Maria ^a   Maravall, Francisco Xavier ^c   Mauricio, Didac ^e,f   Matias Guiu, Xavier ^c   Puig Domingo, Manel ^e,f   Capel, Ismael ^h   Bella, María Rosa ^h   Lerma, Enrique ⁱ   Castella, Eva ^f   Reverter, Jordi Lluis ^e,f,g   Peinado, Miguel Ángel ^b   Jorda, Mireia ^b   Robledo, Mercedes ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b Institute of Predictive and Personalized Medicine of Cancer (IMPPC)   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h HOSPITAL DE SABADELL   (Spain)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

BRAF; Methylation; Prognostic markers; RAS; Well differentiated thyroid cancer

Indexed keywords

B RAF KINASE; GENOMIC DNA; MESSENGER RNA; PEPTIDES AND PROTEINS; PROTEIN EI24; RAS PROTEIN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIFFERENTIATED THYROID CANCER; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC IDENTIFICATION; GENOME; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; VALIDATION STUDY;

BRAF; METHYLATION; PROGNOSTIC MARKERS; RAS; WELL-DIFFERENTIATED THYROID CANCER;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; DNA FINGERPRINTING; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SURVIVAL RATE; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 84901029833     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28703     Document Type: Article

References (50)

1. Kondo T, Ezzat S, Asa SL,. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
2. Nikiforov YE, Nikiforova MN,. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7: 569-80.
3. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085-90.
4. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373-9.
5. Montero-Conde C, Martin-Campos JM, Lerma E, et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 2008; 27: 1554-61.
6. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005; 24: 6646-56.
7. Maliszewska A, Leandro-Garcia LJ, Castelblanco E, et al. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. Am J Pathol 2013; 182: 350-62.
8. Rodriguez-Rodero S, Fernandez AF, Fernandez-Morera JL, et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab 2013; 98: 2811-21.
9. Xing M, Usadel H, Cohen Y, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 2003; 63: 2316-21.
10. Venkataraman GM, Yatin M, Marcinek R, et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999; 84: 2449-57.
11. Hu S, Liu D, Tufano RP, et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 2006; 119: 2322-9.
12. Brait M, Loyo M, Rosenbaum E, et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics 2012; 7: 710-9.
13. Schagdarsurengin U, Gimm O, Hoang-Vu C, et al. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 2002; 62: 3698-701.
14. Bibikova M, Le J, Barnes B, et al. Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 2009; 1: 177-200.
15. Mancuso FM, Montfort M, Carreras A, et al. HumMeth27QCReport: an R package for quality control and primary analysis of Illumina Infinium methylation data. BMC Res Notes 2011; 4: 546.
16. Du P, Zhang X, Huang CC, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010; 11: 587.
17. Morrissey ER, Diaz-Uriarte R,. Pomelo II: finding differentially expressed genes. Nucleic Acids Res 2009; 37: W581-6.
18. Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res 2012; 22: 1197-211.
19. Huang da W, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
20. Zhuang J, Jones A, Lee SH, et al. The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet 2012; 8: e1002517.
21. Varley KE, Gertz J, Bowling KM, et al. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Res 2013; 23: 555-67.
22. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 11891-6.
23. Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2012; 22: 407-19.
24. Arora N, Scognamiglio T, Zhu B, et al. Do benign thyroid nodules have malignant potential? An evidence-based review. World J Surg 2008; 32: 10.
25. Hinoue T, Weisenberger DJ, Lange CP, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012; 22: 271-82.
26. Hinoue T, Weisenberger DJ, Pan F, et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 2009; 4: e8357.
27. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-4.
28. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38: 787-93.
29. Shen L, Toyota M, Kondo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104: 18654-9.
30. Hou P, Liu D, Xing M,. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer 2011; 18: 687-97.
31. Li J, Harris RA, Cheung SW, et al. Genomic hypomethylation in the human germline associates with selective structural mutability in the human genome. PLoS Genet 2012; 8: e1002692.
32. Rodriguez J, Frigola J, Vendrell E, et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 2006; 66: 8462-9468.
33. Ward LS, Brenta G, Medvedovic M, et al. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 1998; 83: 525-30.
34. Suzuki H, Igarashi S, Nojima M, et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 2010; 31: 342-9.
35. Zhu J, Woods D, McMahon M, et al. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12: 2997-3007.
36. Vizioli MG, Possik PA, Tarantino E, et al. Evidence of oncogene-induced senescence in thyroid carcinogenesis. Endocr Relat Cancer 2011; 18: 743-57.
37. Cheung M, Sharma A, Madhunapantula SV, et al. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008; 68: 3429-39.
38. Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001; 61: 6105-11.
39. Faustino A, Couto JP, Populo H, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: E1139-49.
40. Borgono CA, Diamandis EP,. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-90.
41. Olkhov-Mitsel E, Van der Kwast T, Kron KJ, et al. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 2012; 7: 1037-45.
42. Roth JM, Akalu A, Zelmanovich A, et al. Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol 2005; 166: 901-11.
43. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008; 99: 375-82.
44. Wang Z, Li L, Su X, et al. Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas. J Transl Med 2012; 10: 209.
45. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
46. Mazumder Indra D, Mitra S, Singh RK, et al. Inactivation of CHEK1 and EI24 is associated with the development of invasive cervical carcinoma: clinical and prognostic implications. Int J Cancer 2011; 129: 1859-71.
47. Mork CN, Faller DV, Spanjaard RA,. Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett 2007; 581: 5440-4.
48. Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002; 16: 1381-9.
49. Weisser M, Kern W, Rauhut S, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416-23.
50. Kobayashi Y, Absher DM, Gulzar ZG, et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 2011; 21: 1017-27.